Hansa Biopharma Ab Stock Working Capital
| HNSA Stock | SEK 31.00 0.50 1.59% |
Hansa Biopharma AB fundamentals help investors to digest information that contributes to Hansa Biopharma's financial success or failures. It also enables traders to predict the movement of Hansa Stock. The fundamental analysis module provides a way to measure Hansa Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hansa Biopharma stock.
Hansa |
Hansa Biopharma AB Company Working Capital Analysis
Hansa Biopharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
According to the company's disclosures, Hansa Biopharma AB has a Working Capital of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The working capital for all Sweden stocks is 100.0% higher than that of the company.
Hansa Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hansa Biopharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hansa Biopharma could also be used in its relative valuation, which is a method of valuing Hansa Biopharma by comparing valuation metrics of similar companies.Hansa Biopharma is currently under evaluation in working capital category among its peers.
Hansa Fundamentals
| Return On Equity | -0.89 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (3.80) % | |||
| Current Valuation | 2.17 B | |||
| Shares Outstanding | 52.44 M | |||
| Shares Owned By Insiders | 7.37 % | |||
| Shares Owned By Institutions | 41.33 % | |||
| Price To Book | 7.52 X | |||
| Price To Sales | 17.67 X | |||
| Revenue | 154.53 M | |||
| Gross Profit | 116.05 M | |||
| EBITDA | (585.52 M) | |||
| Net Income | (609.57 M) | |||
| Cash And Equivalents | 762.73 M | |||
| Cash Per Share | 19.06 X | |||
| Total Debt | 783.93 M | |||
| Debt To Equity | 1.60 % | |||
| Current Ratio | 15.45 X | |||
| Book Value Per Share | 11.55 X | |||
| Cash Flow From Operations | (504.36 M) | |||
| Earnings Per Share | (13.10) X | |||
| Target Price | 171.0 | |||
| Number Of Employees | 150 | |||
| Beta | 0.88 | |||
| Market Capitalization | 2.82 B | |||
| Total Asset | 1.69 B | |||
| Z Score | 1.8 | |||
| Net Asset | 1.69 B |
About Hansa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hansa Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hansa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hansa Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hansa Stock Analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.